Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AURANASDAQ:NEO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAURAAura Biosciences$6.04-1.0%$5.85$4.35▼$12.38$303.63M0.43210,229 shs296,962 shsNEONeoGenomics$7.00+0.7%$8.01$6.08▼$19.12$900.90M1.651.25 million shs2.35 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAURAAura Biosciences0.00%-5.92%+2.55%-13.71%-16.11%NEONeoGenomics0.00%-0.99%-5.53%-31.10%-46.85%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAURAAura Biosciences1.6039 of 5 stars3.61.00.00.00.03.30.0NEONeoGenomics4.0801 of 5 stars4.25.00.00.01.53.31.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAURAAura Biosciences 3.25Buy$22.00264.24% UpsideNEONeoGenomics 2.45Hold$13.8397.62% UpsideCurrent Analyst Ratings BreakdownLatest BKY, AURA, NEO, and YCA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2025AURAAura BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$22.005/23/2025AURAAura BiosciencesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$19.005/15/2025NEONeoGenomicsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral5/6/2025NEONeoGenomicsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOverweight ➝ Overweight$18.00 ➝ $12.005/1/2025NEONeoGenomicsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$17.00 ➝ $10.004/30/2025NEONeoGenomicsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/30/2025NEONeoGenomicsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $10.004/30/2025NEONeoGenomicsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform$25.00 ➝ $9.004/29/2025NEONeoGenomicsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$18.00 ➝ $8.504/17/2025NEONeoGenomicsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$17.00 ➝ $15.003/26/2025AURAAura BiosciencesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$19.00(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAURAAura BiosciencesN/AN/AN/AN/A$3.04 per shareN/ANEONeoGenomics$660.57M1.36$0.44 per share15.96$7.03 per share1.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAURAAura Biosciences-$86.92M-$1.90N/AN/AN/AN/A-58.63%-49.74%8/14/2025 (Estimated)NEONeoGenomics-$78.73M-$0.61N/A77.78N/A-11.54%-2.21%-1.22%8/4/2025 (Estimated)Latest BKY, AURA, NEO, and YCA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025AURAAura Biosciences-$0.47-$0.55-$0.08-$0.55N/AN/A4/29/2025Q1 2025NEONeoGenomics-$0.02-$0.08-$0.06-$0.20$171.38 million$168.04 million3/24/2025Q4 2024AURAAura Biosciences-$0.43-$0.52-$0.09-$0.52N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAURAAura BiosciencesN/AN/AN/AN/AN/ANEONeoGenomicsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAURAAura BiosciencesN/A11.0611.06NEONeoGenomics0.382.051.95Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAURAAura Biosciences96.75%NEONeoGenomics98.50%Insider OwnershipCompanyInsider OwnershipAURAAura Biosciences5.40%NEONeoGenomics2.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAURAAura Biosciences5050.27 million47.55 millionNot OptionableNEONeoGenomics2,200128.70 million125.61 millionOptionableBKY, AURA, NEO, and YCA HeadlinesRecent News About These CompaniesAdvisor Resource Council Makes New $872,000 Investment in NeoGenomics, Inc. (NASDAQ:NEO)June 22 at 4:23 AM | marketbeat.comNeoGenomics, Inc. (NASDAQ:NEO) Given Average Rating of "Hold" by AnalystsJune 18, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zeo Energy Corp. - ZEOJune 17, 2025 | prnewswire.comNeoGenomics (NASDAQ:NEO) Sees Strong Trading Volume - Here's What HappenedJune 16, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zeo Energy Corp. - ZEOJune 16, 2025 | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zeo Energy Corp. - ZEOJune 15, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zeo Energy Corp. - ZEOJune 13, 2025 | accessnewswire.comNeoGenomics (NASDAQ:NEO) Stock Price Down 5.2% - Here's WhyJune 12, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zeo Energy Corp. - ZEOJune 12, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zeo Energy Corp. - ZEOJune 11, 2025 | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zeo Energy Corp. - ZEOJune 9, 2025 | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zeo Energy Corp. - ZEOJune 7, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zeo Energy Corp. - ZEOJune 4, 2025 | accessnewswire.comNeoGenomics, Inc. (NASDAQ:NEO) Short Interest Up 32.2% in MayJune 3, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zeo Energy Corp. - ZEOJune 3, 2025 | accessnewswire.comNeoGenomics, Inc. (NASDAQ:NEO) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLCJune 1, 2025 | marketbeat.comNuveen Asset Management LLC Sells 98,179 Shares of NeoGenomics, Inc. (NASDAQ:NEO)June 1, 2025 | marketbeat.comNeoGenomics, Inc. (NASDAQ:NEO) Director Michael Aaron Kelly Purchases 5,000 SharesMay 30, 2025 | marketbeat.comNeoGenomics unveils new oncology diagnostics at ASCO 2025May 29, 2025 | investing.comFort Myers-based NeoGenomics to unveil new cancer diagnostics at ASCO 2025May 29, 2025 | gulfshorebusiness.comNeoGenomics, Inc. (NASDAQ:NEO) Director Buys $38,000.00 in StockMay 29, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBKY, AURA, NEO, and YCA Company DescriptionsAura Biosciences NASDAQ:AURA$6.04 -0.06 (-0.98%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$6.02 -0.01 (-0.25%) As of 06/20/2025 06:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.NeoGenomics NASDAQ:NEO$7.00 +0.05 (+0.72%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$7.09 +0.09 (+1.29%) As of 06/20/2025 06:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
